ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

World Conference To Consider Smoking Problem, Research, Action

March 14, 1975

No Controversy Over Cancer Act This Time

May 25, 1990

Edelson to Direct Yale Cancer Center (12-page issue).

May 30, 2003

Committee Unblinds Phase III Zytiga Study

March 30, 2012

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

November 16, 1979

In Brief: Takeo Kakanaga Dies; President’s Cancer Panel to Meet Nov. 7; Young To Give Schwartz Lecture

October 7, 1988